ARTICLE | Distillery Therapeutics
Degrading FOXO1 via KIND2 inhibition for NAFLD
April 1, 2022 5:06 AM UTC
DISEASE CATEGORY: Hepatic disease
INDICATION: Liver disease...
BCIQ Company Profiles
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
DISEASE CATEGORY: Hepatic disease
INDICATION: Liver disease...
BCIQ Company Profiles
BCIQ Company Profiles